Optimización de las estrategias de retención, duración y descontinuación para la farmacoterapia del trastorno por consumo de opioides (RDD)
NIDA-CTN-0100: Optimización de las estrategias de retención, duración y descontinuación para la farmacoterapia del trastorno por consumo de opioides (RDD)
This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
The main objectives of this study are:
- To test strategies to improve retention in treatment on medications for opioid use disorder (MOUD), among patients initiating treatment for OUD.
- To test strategies to improve outcomes among patients who have achieved stable remission on MOUD and want to discontinue MOUD.
- To develop models to predict who is able to discontinue MOUD without relapse, based on patient characteristics, including duration of MOUD prior to discontinuation.
The study will have a multicenter, randomized, pragmatic non-blinded design. The study has two phases, a Retention Phase and a Discontinuation Phase.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)
-
-
California
-
Tarzana, California, Estados Unidos, 91356
- Tarzana Treatment Centers, Inc.
-
-
Connecticut
-
Bridgeport, Connecticut, Estados Unidos, 06610
- Liberation Programs, Inc.
-
-
Florida
-
Clearwater, Florida, Estados Unidos, 33760
- Operation PAR
-
Jacksonville, Florida, Estados Unidos, 32204
- Gateway Community Services
-
Orlando, Florida, Estados Unidos, 32806
- Aspire Health Partners
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21229
- Mountain Manor / Maryland Treatment Centers
-
-
Massachusetts
-
Belmont, Massachusetts, Estados Unidos, 02478
- McLean Hospital
-
Fall River, Massachusetts, Estados Unidos, 02720
- Stanley Street Treatment and Resources, Inc.
-
Newton, Massachusetts, Estados Unidos, 02458
- Square Medical Group, LLC
-
-
Missouri
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Gibson Center for Behavioral Change
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03766
- Dartmouth Hitchcock - ATP
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- University of New Mexico Addiction and Substance Abuse Program
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Bellevue Hospital Center
-
-
Oregon
-
Roseburg, Oregon, Estados Unidos, 97470
- Adapt Integrated Health Care
-
Winston, Oregon, Estados Unidos, 97496
- Adapt Integrated Health Care
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- Center for Psychiatric and Chemical Dependency Services (CPCDS)
-
Pittsburgh, Pennsylvania, Estados Unidos, 15219
- Internal Medicine Recovery Engagement Program (IM-REP)
-
-
South Carolina
-
Conway, South Carolina, Estados Unidos, 29526
- Shoreline Behavioral Health Services
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84108
- Huntsman Mental Health Institute / University of Utah
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26505
- Chestnut Ridge Center
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria for Retention Phase:
- 18 years of age or older;
- Meet DSM-5 criteria for current opioid use disorder (heroin, fentanyl or other synthetic opioids, and/or prescription opioids);
- Seeking treatment for opioid use disorder and choosing either buprenorphine (BUP) or extended-release injection naltrexone (XR-NTX);
- If choosing buprenorphine, willing to be randomized to SL-BUP-16mg, SL-BUP-32mg, or XR-BUP;
- Willing to be randomized to either MM (standard Medical Management plus counseling treatment as usual available at the site) or MMR (MM plus usual counseling and access to an app delivering CM + CBT);
- In good-enough general health (meaning good enough health to be in outpatient treatment) as determined by the study medical clinician on the basis of medical history, review of systems, and physical/mental status exam, to permit treatment with XR-NTX or BUP;
- Willing and able to provide written informed consent;
- Able to speak English sufficiently to understand the study procedures;
- If female of childbearing potential, willing to practice an effective method of birth control for the duration of participation in the study (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).
Exclusion Criteria for Retention Phase:
-
Serious medical, psychiatric, or co-occurring substance use disorder or concomitant medication that, in the opinion of the study medical clinician, makes the patient not appropriate for outpatient treatment with buprenorphine or XR-NTX, but instead requires a higher or different level of care. Examples include:
- Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
- Severe, untreated or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
- Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use, requiring a different level of care (e.g., hospitalization);
-
Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);
-
Known allergy or sensitivity to preferred medication or its components;
-
Maintenance on methadone at the time of signing consent;
-
For those preferring XR-NTX, presence of pain of sufficient severity as to require ongoing pain management with opioids;
-
For those preferring XR-NTX, body habitus that, in the judgment of the study physician, precludes safe intramuscular injection of XR-NTX (e.g., BMI>40, excess fat tissue over the buttocks, emaciation);
-
If female, currently pregnant or breastfeeding or planning on conception;
-
Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;
-
Have used the reSET-O or CHESS Connections mHealth apps in the 3 months prior to consent;
-
Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area).
Inclusion Criteria for Discontinuation Phase:
- 18 years of age or older;
- Have been receiving buprenorphine for OUD for at least the past year or XR-NTX pharmacotherapy for OUD for at least the past 6 months prior to consent for the Discontinuation Phase;
- Express the desire to discontinue MOUD after a shared decision-making discussion with the treating provider;
- Meet stability criteria, i.e., have abstained from opioids (other than buprenorphine), cocaine, methamphetamine, and non-prescribed benzodiazepines for the past ≥12 weeks, and do not meet DSM-5 criteria for current (≥12 weeks) alcohol use disorder (participants with cannabis use will be eligible);
- If currently taking buprenorphine, are willing to take either SL-BUP or XR-BUP if randomized to that condition;
- Willing to be randomized to either MM or to MMD;
- Able to provide written informed consent after discussion with their provider regarding the risks of discontinuation;
- Able to speak English sufficiently to understand the study procedures;
- If female of childbearing potential, willing to practice an effective method of birth control while in the study and taking study medication (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).
Exclusion Criteria for Discontinuation Phase:
-
Serious medical or psychiatric disorder or concomitant medication that, in the opinion of the study medical clinician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include:
- Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
- Severe, untreated, or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
-
Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);
-
For participants entering the study taking buprenorphine, presence of pain requiring or likely requiring ongoing pain management with buprenorphine or other opioids;
-
If female, currently pregnant or breastfeeding or planning on conception;
-
Use of opioids (other than buprenorphine), cocaine, methamphetamine, or non-prescribed benzodiazepines in the past 12 weeks;
-
Meets current DSM-5 criteria for any current alcohol use disorder;
-
Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;
-
Have used the Connections mHealth app in the 3 months prior to consent (other than Connections in the Retention Phase);
-
Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación factorial
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Retention: SL-BUP standard dose + MM
Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
Daily dosing of sublingual buprenorphine-naloxone
Otros nombres:
MM consists of standard Medical Management and the usual counseling at the treatment program. |
|
Experimental: Retention: SL-BUP high dose + MM
High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
Daily dosing of sublingual buprenorphine-naloxone
Otros nombres:
MM consists of standard Medical Management and the usual counseling at the treatment program. |
|
Experimental: Retention: XR-BUP + MM
Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Weekly/monthly dosing of extended-release injectable buprenorphine
Otros nombres:
|
|
Experimental: Retention: XR-NTX + MM
Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Monthly dosing of extended-release injectable naltrexone
Otros nombres:
|
|
Experimental: Retention: SL-BUP standard dose + MMR
Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus a technology-based behavioral component. |
Daily dosing of sublingual buprenorphine-naloxone
Otros nombres:
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimental: Retention: SL-BUP high dose + MMR
High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Daily dosing of sublingual buprenorphine-naloxone
Otros nombres:
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimental: Retention: XR-BUP + MMR
Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Weekly/monthly dosing of extended-release injectable buprenorphine
Otros nombres:
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimental: Retention: XR-NTX + MMR
Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Monthly dosing of extended-release injectable naltrexone
Otros nombres:
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimental: Discontinuation: Discontinue SL-BUP with SL-BUP + MM
Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
Daily dosing of sublingual buprenorphine-naloxone
Otros nombres:
MM consists of standard Medical Management and the usual counseling at the treatment program. |
|
Experimental: Discontinuation: Discontinue SL-BUP with XR-BUP + MM
Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Weekly/monthly dosing of extended-release injectable buprenorphine
Otros nombres:
|
|
Experimental: Discontinuation: Discontinue XR-BUP with XR-BUP + MM
Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Weekly/monthly dosing of extended-release injectable buprenorphine
Otros nombres:
|
|
Experimental: Discontinuation: Discontinue XR-NTX with XR-NTX + MM
Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Monthly dosing of extended-release injectable naltrexone
Otros nombres:
|
|
Experimental: Discontinuation: Discontinue SL-BUP with SL-BUP + MMD
Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Daily dosing of sublingual buprenorphine-naloxone
Otros nombres:
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimental: Discontinuation: Discontinue SL-BUP with XR-BUP + MMD
Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Weekly/monthly dosing of extended-release injectable buprenorphine
Otros nombres:
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimental: Discontinuation: Discontinue XR-BUP with XR-BUP + MMD
Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Weekly/monthly dosing of extended-release injectable buprenorphine
Otros nombres:
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimental: Discontinuation: Discontinue XR-NTX with XR-NTX + MMD
Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Monthly dosing of extended-release injectable naltrexone
Otros nombres:
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Retention: Continuous retention in MOUD treatment through 26 weeks
Periodo de tiempo: Retention: from randomization through week 26
|
Binary (yes/no). Continuously enrolled in maintenance treatment on one or more of the evidence-based MOUD modalities (e.g., SL-BUP, XR-BUP, XR-NTX, or methadone maintenance) with no more than a 28-day gap on MOUD over the 26-week period. |
Retention: from randomization through week 26
|
|
Discontinuation: Completed Discontinuation without Relapse
Periodo de tiempo: Discontinuation: from randomization through week 24 follow up
|
Binary (yes/no). Discontinuing MOUD during the taper period, no return to MOUD, and no relapse to opioid use, either during the taper (up to 48 weeks for those entering on BUP or 24 weeks for those entering on XR-NTX) or during the 24 weeks after MOUD is discontinued. |
Discontinuation: from randomization through week 24 follow up
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Retention KS1: Weekly opioid abstinence
Periodo de tiempo: Retention: from randomization through week 26
|
Weekly opioid abstinence (measured by Timeline Followback, not contradicted by toxicology test). Repeated yes/no measure for each of weeks 1 through 26. |
Retention: from randomization through week 26
|
|
Retention KS2: Treatment effectiveness
Periodo de tiempo: Retention: at week 26
|
Retention treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 26. |
Retention: at week 26
|
|
Retention KS3: Treatment by baseline severity
Periodo de tiempo: Retention: at week 26
|
Treatment by baseline severity interaction where severity is indicated by the randomization stratum injection use (yes/no). |
Retention: at week 26
|
|
Discontinuation KS1: Completed Discontinuation
Periodo de tiempo: Discontinuation: from randomization through week 24 follow up
|
Completed Discontinuation without regard to relapse status |
Discontinuation: from randomization through week 24 follow up
|
|
Discontinuation KS2: Relapse
Periodo de tiempo: Discontinuation: from randomization through week 24 follow up
|
Relapse - separate binary outcome without regard to discontinuation status |
Discontinuation: from randomization through week 24 follow up
|
|
Discontinuation KS3: Safety
Periodo de tiempo: Discontinuation: from randomization through week 24 follow up
|
Safety outcomes (binary, any one or more occurrences): overdoses, all non-fatal plus fatal. |
Discontinuation: from randomization through week 24 follow up
|
|
Discontinuation KS4: Treatment effectiveness
Periodo de tiempo: Discontinuation: at end of taper (EoT) and week 24 follow up
|
Discontinuation treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 24. Measured at the end of taper (EOT): up to 24 weeks for tapers with XR-NTX and up to 48 weeks for tapers with BUP; and at the week 24 follow up (primary outcome timepoint). |
Discontinuation: at end of taper (EoT) and week 24 follow up
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Edward V Nunes, MD, New York State Psychiatric Institute/Columbia University Irving Medical Center
- Investigador principal: Roger Weiss, MD, Harvard Medical School/McLean Hospital
- Investigador principal: John Rotrosen, MD, NYU Langone Health
Publicaciones y enlaces útiles
Publicaciones Generales
- Shulman M, Meyers-Ohki S, Novo P, Provost S, Ohrtman K, Van Veldhuisen P, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Weiss RD, Nunes EV. Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD). Contemp Clin Trials. 2025 Mar;150:107816. doi: 10.1016/j.cct.2025.107816. Epub 2025 Jan 20.
- Shulman M, Provost S, Ohrtman K, Novo P, Meyers-Ohki S, Van Veldhuisen P, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Nunes EV, Weiss RD. Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial. Contemp Clin Trials. 2024 Jul;142:107543. doi: 10.1016/j.cct.2024.107543. Epub 2024 Apr 23.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Trastornos relacionados con narcóticos
- Desordenes mentales
- Trastornos relacionados con sustancias
- Trastornos inducidos químicamente
- Trastornos relacionados con opioides
- Compuestos heterocíclicos
- Compuestos heterocíclicos, anillo fusionado
- Preparaciones farmacéuticas
- Alcaloides
- Hidrocarburos aromáticos policíclicos
- Compuestos policíclicos
- Compuestos heterocíclicos, 4 o más anillos
- Combinaciones de drogas
- Naloxona
- Morfinanos
- Alcaloides opiáceos
- Compuestos heterocíclicos, anillo puente
- Fenantrenos
- Combinación de fármacos de buprenorfina y naloxona
- Buprenorfina
- vivitrol
Otros números de identificación del estudio
Otros números de identificación del estudio
- 19-01363
- UG1DA015831 (Subvención/contrato del NIH de EE. UU.)
- CTN-0100 (Otro identificador: NIDA Clinical Trials Network)
- UG1DA013035 (Subvención/contrato del NIH de EE. UU.)
- 20-PRS-057 (Otro identificador: Biomedical Research Alliance of New York (BRANY) sIRB)
- 146193 (Otro identificador: FDA/IND#)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
This study will comply with the NIH Data Sharing Policy and Implementation Guidance (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm) and (for HEAL-funded studies) the HEAL Public Access and Data Sharing Policy (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/research/heal-public-access-data-sharing-policy).
Primary data for this study will be available to the public in the NIDA data repository. For more details on data sharing please visit https://datashare.nida.nih.gov/.
The primary outcome(s) publication will be included along with study underlying primary data in the data share repository, and it will also be deposited in PubMed Central http://www.pubmedcentral.nih.gov/ per NIH Policy (http://publicaccess.nih.gov/).
Marco de tiempo para compartir IPD
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .